Duodenal intraepithelial lymphocytosis during Helicobacter pylori infection is reduced by antibiotic treatment.
OBJECTIVE
To evaluate clinical, biological and immunological features of patients with increased duodenal intraepithelial lymphocytes (IELs), and its relation to Helicobacter pylori (HP) and coeliac disease (CD).


METHODS
We have studied all patients accrued over a 4-year period with increased duodenal IELs. Those patients were recalled for biological and immunological evaluation and a second endoscopy.


RESULTS
Twenty-three from a total of 639 patients were identified and 17 of them were included in the study. The median duodenal IEL count was 59 per 100 epithelial cells. Twelve (71%) patients were HP+; eight of them received HP eradication. At the second endoscopy the duodenal IEL count was significantly lower 2 months after HP eradication (73 versus 28), while the IEL count was unchanged in those patients seronegative for HP (n = 5) or those in whom it was not eradicated (n = 4) (55 versus 55). No patient had coeliac antibodies, four expressed HLA-DQ2, lower than in the general population, and the prevalence of CD was 2% (12/639 patients).


CONCLUSIONS
In some cases an increased duodenal IEL count may be due to an inappropriate host response to HP. HP screening and eradication should be considered before recommending a gluten-free diet.
Service d'Anatomopathologie, Centre Hospitalier Intercommunal, Le Raincy-Montfermeil, France.
S
S
Nahon
N
N
Patey-Mariaud De Serre
O
O
Lejeune
F-X
FX
Huchet
P
P
Lahmek
B
B
Lesgourgues
L
L
Traissac
V
V
Bodiguel
F
F
Adotti
T
T
Tuszynski
N
N
Delas
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001706:Biopsy; D002446:Celiac Disease / Q000150:complications / Q000276:immunology; D002452:Cell Count; D004386:Duodenum / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology; D016099:Endoscopy, Gastrointestinal; D004848:Epithelium / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D005260:Female; D006683:HLA-DQ Antigens / Q000276:immunology; D059866:HLA-DQ beta-Chains; D015804:HLA-DR4 Antigen / Q000276:immunology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008214:Lymphocytes / Q000473:pathology; D008218:Lymphocytosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D013270:Stomach / Q000187:drug effects / Q000382:microbiology / Q000473:pathology
D000900:Anti-Bacterial Agents; D006683:HLA-DQ Antigens; D059866:HLA-DQ beta-Chains; C069051:HLA-DQB1 antigen; D015804:HLA-DR4 Antigen